Introduction
============

Chemotherapeutics cardiotoxicity is a major concern for clinicians treating different kinds of cancer, as it seriously affects their treatment options and the survival of the patient. The cut-off values for the identification of cardiotoxicity caused by chemotherapeutics in humans differ between the American and European guidelines: the definition considers a lower cut-off value of normality for the left ventricular ejection fraction (LVEF) of 50% in Europe ([@b1-or-44-03-0798]) and 53% in the USA ([@b2-or-44-03-0798]). Both Guidelines emphasize that a drop of LVEF compared to the patient\'s previous values is also required. This definition is crucial for patients and clinicians, as patients presenting this decline in cardio-imaging indices of cardiac function should be treated with angiotensin converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) in combination with β-blockers ([@b3-or-44-03-0798]); nevertheless, modifications of anticancer treatment in such patients remain a matter of discussion among different specialists.

In animal studies, where new anticancer substances are evaluated and different agents are tested to overcome anticancer drugs cardiotoxicity, identification of the extent of cardiotoxicity is crucial and necessary for the evaluation of any favourable effects of the counteracting agent ([@b4-or-44-03-0798]). In this regard, cardiac imaging is more often used at analogy to the clinical setting. Biomarkers and clinical signs of heart failure are also taken into consideration, but cardiac imaging in animal studies has gained momentum.

Anthracyclines are a class of drugs used in cancer chemotherapy isolated from *Streptomyces bacterium*. These compounds are used to treat many cancers, including leukemias, lymphomas, as well as breast, stomach, uterine, ovarian, bladder cancer, and lung cancers ([@b5-or-44-03-0798]--[@b7-or-44-03-0798]). The first anthracycline discovered was daunorubicin (trade name Daunomycin), which is produced naturally by *Streptomyces peucetius*, a species of actinobacteria. Clinically, the most important anthracyclines are doxorubicin, daunorubicin, epirubicin and idarubicin. Anthracyclines, which are considered as well-established cardiotoxic compounds causing myocardial suppression in a considerable number of patients, are also used in animal studies as an easy and low-cost method to introduce a model of dilated cardiomyopathy ([@b8-or-44-03-0798]), as opposed to interventional research animal models of infarction and myocardial ischaemia \[e.g., permanent ligation of the left anterior descending artery (LAD) or cryo-pen application on the surface of the heart leading to cryo-scar ischemia\]. Different animal species and various anthracyclines dosing and administration schemes have been applied in the literature for the development of anthracyclines cardiotoxicity ([@b9-or-44-03-0798]) and monitoring of the progress thereof, as well as testing different compounds/schemes for ameliorating myocardial damage. To monitor cardiotoxicity caused by anthracyclines, cardiac imaging is primarily used and secondarily, biochemical markers.

At the same time, other pharmaceutical compounds, such as anabolic steroids, along with everyday chemicals, such as metals and pesticides, have been implicated to adversely affect cardiac pathology causing function impairment ([@b10-or-44-03-0798]). Toxicity and risk for human health posed by chemicals are well controlled at a European level through a thoroughly developed regulatory network. Nevertheless, cardiotoxicity is not described as a separate hazard class and no specific classification criteria are available in order to legally classify chemicals well in advance as cardiotoxic and avoid potential long-term cardiovascular complications, which could significantly burden any national health system.

But, what is considered cardiotoxicity of anticancer agents and specifically anthracyclines when parameters of cardiac imaging are monitored in animal studies? Is there a uniformity in animal models of anthracyclines cardiotoxicity induction and most importantly, do all studies describe the same decline of myocardial function? Addressing these issues could be of wider use both in clinical medicine and practice, when assessing agents employed for salvation to cardiotoxic complications during oncology treatment, for example, as well as to regulators, when trying to establish reference values in echocardiographic function representing cardiotoxicity induced in animals by chemicals.

In the current in depth review, the identification of most commonly used metrics of myocardial function in animal studies of anthracycline induced cardiotoxicity are presented, along with the range of these values differentiating normal cardiac function from animals with pathological echocardiographic findings indicative of anthracycline cardiotoxicity as per author presentation.

Materials and methods
=====================

PubMed electronic database was systematically searched to detect all original research studies published until March 1, 2020, according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement ([@b11-or-44-03-0798]). The specific literature search strategy used was: \[AND ("\*rats\*" OR "\*doxorubicin\* OR "\*echocardiography\*" OR "anthracycline" OR "\*ejection fraction\*")\] either in the Title, or the Abstracts. The reference list of the retrieved studies was further evaluated for the relevance of the subject and the eligibility by screening the titles/abstracts of full papers. The non-English citations (\<5) were reviewed separately. Animal data only from rat species were assessed, as it is evident from the search string. All types of citations other than original research studies (e.g., review articles) were excluded. Two authors (NG and CT) independently assessed the title and the abstract content (or both) of each record retrieved to decide which studies should be further evaluated and extracted all data. Disagreements were resolved through consensus or by consultation with a third author (KT). A final draft of the manuscript was prepared after several revisions and approved by all authors. In total, 86 published manuscripts on animal studies were considered for the systematic review ([Fig. 1](#f1-or-44-03-0798){ref-type="fig"}).

Despite the small size of the rat heart and the fast heart rate, echocardiography is systematically used in the evaluation of rat heart function ([@b12-or-44-03-0798]). Data for 2 main indices of LV contractility were extracted from the list of studies.

The first index is LV fractional shortening (FS) and is calculated by the formula: FS (%) = \[LV end-diastolic diameter (LVD~d~) minus LV end-systolic diameter (LVD~s~)\]/LVD~d~ × 100.

LVEF is the second and more common, index of LV contractility. EF can be calculated from the equation: EF (%) = \[(LVD~d~^3^ - LVD~s~^3^) / LVD~d~^3^\] × 100 ([@b13-or-44-03-0798]) or from the equation: EF (%) = (LVEDV-LVESV)/LVEDV × 100, where LVEDV is the LV end-diastolic volume and LVESV is LV end-systolic volume ([@b12-or-44-03-0798]).

Results
=======

A summary of the studies reviewed in the present report is presented in [Table I](#tI-or-44-03-0798){ref-type="table"}.

In [Figs. 2](#f2-or-44-03-0798){ref-type="fig"}--[5](#f5-or-44-03-0798){ref-type="fig"}, the normal and suppressed values of the two main echocardiographic indices discussed, %EF and %FS, respectively, are presented. Reported baseline (normal) %EF values in rats vary (55-96.5%). In 78.2% of the studies reviewed, normal values range from 70 to 90%. High %EF values (\>90%) are reported in 14% of the studies. In contrast, normal %FS values present even higher variability (25-84.2%). The majority (66.7%) of the values, though, are reported to be within the range of 40 and 60%.

Exposure to anthracyclines suppresses both echocardiographic indices. In the 86 studies reviewed in the present report, Doxorubicin is almost universally used to induce cardiotoxicity, along with Daunorubicin and Epirubicin in two studies ([Table I](#tI-or-44-03-0798){ref-type="table"}). The structures of the three anthracyclines used are presented in [Fig. 6](#f6-or-44-03-0798){ref-type="fig"}. Anthracyclines were administered with order of appearance either via intraperitoneal injection, intravenous injection or orally with the feed. The doses were administered once, twice, three times per week. The duration of the dose administration spans from one week to ten weeks. In most of the experiments, the benchmark for terminating the administration was the proof of cardiac toxicity. The echocardiography values suggest that there is no specific dose regime threshold which indicates the establishment of the effect, but it is specific to each experiment and probably dependent on other factors such as age and general condition of the animals.

The suppressed %EF values reported from rats after anthracyclines administration vary from 31 to 91% ([Fig. 4](#f4-or-44-03-0798){ref-type="fig"}). EF values 50--80% are reported in 72.3% of the studies reviewed. Suppression of the %EF due to anthracycline administration varies from 10 to 40% compared to the normal values in more than two thirds of the studies reviewed (71.7%) ([Fig. 7](#f7-or-44-03-0798){ref-type="fig"}). On the other hand, suppressed %FS values ranging from 14 to 71.8%, present a more narrow distribution (%FS values 20--50% in 84.6% of the studies). As shown in [Fig. 7](#f7-or-44-03-0798){ref-type="fig"}, a more equal distribution of the %FS suppression due to anthracycline toxicity is observed with approximately one fourth of the studies reporting 20--30% and 30--40% suppression, respectively. It is evident from [Figs 8](#f8-or-44-03-0798){ref-type="fig"} and [9](#f9-or-44-03-0798){ref-type="fig"} that normal and suppressed %EF and %FS values separate sufficiently well. The rat strain does not seem to influence either the normal or the suppressed %EF and %FS values ([Fig. 10](#f10-or-44-03-0798){ref-type="fig"}).

Only 11 studies used an acute administration scheme, with 3--20 mg/kg bw anthracycline single injection either intravenously or intraperitoneally. Most of the studies used a prolonged administration period, from 2 weeks (33 studies) up to 10 weeks, and cumulative doses ranging from 1 to 20 mg/kg bw. All dosage schemes were carefully selected to induce cardiotoxicity and did not seem to affect the suppression of %EF and %FS monitored.

Discussion
==========

Myocardial contractility suppression due to anthracycline administration is of increasing interest and represents a major challenge in the clinical setting. At the same time in a preclinical stage it serves as a model for the assessment of both new chemotherapeutic and cardioprotective agents to be introduced in clinical practice. The myocardial toxicity of anthracyclines is known to be affected by sex and age, along with a number of cardiovascular risk factors and comorbidities ([@b99-or-44-03-0798]). It is found that anthracycline related congestive heart failure reaches 10% of patients older than 65 years at usual doses ([@b100-or-44-03-0798]). While in early studies it was thought that EF cannot accurately predict congestive heart failure attributed to doxorubicin ([@b100-or-44-03-0798]), current perspective is that anthracycline-related cardiotoxicity is manifested by a progressive continuous decline in LVEF ([@b1-or-44-03-0798]) and identifying subclinical myocardial dysfunction related to anthracycline treatment has great therapeutic implications ([@b2-or-44-03-0798]).

Preclinical animal studies are essential in cancer chemotherapy research along with the evaluation of the cardiotoxic propensity of the chemotherapeutic agents. The current recommendations for prevention of cardiac events from cancer chemotherapies are largely based on recommendations. The American Society of Clinical Oncology, for example, recommends active screening and prevention of modifiable cardiovascular risk factors, such as tobacco use, high blood pressure, high cholesterol, alcohol use, obesity and physical inactivity ([@b101-or-44-03-0798]). A well characterized animal model for defining cardiotoxicity due to chemotherapy and the treatment thereof is of great importance for clinical practice, as it will enable physicians to base their decisions not only on epidemiology but also on observations developed using concrete data from animal studies.

In the present review, the range of the main echocardiographic indices, namely EF and FS, used in describing anthracycline cardiotoxicity in rats was summarized along with the normal values of the said indices presented in the respective studies. In the graphic representation, it seems that normal and suppressed values due to anthracyclines administration for the two echocardiographic indices are well separated. This provides the first evidence for the possibility of setting a cut-off point for defining anthracycline cardiotoxicity in rats with an in-depth future meta-analysis.

In the current study a wide range of EF and FS decline due to anthracycline administration was observed. However, the trends of the said decline are easily identified, especially for FS values, thus rendering the establishment of minimum cut off values of decline feasible. The question remains, as it has also been identified for humans, whether the absolute suppressed values of EF and FS, combined or separately, or the % suppression caused by anthracyclines should be used to describe cardiotoxicity, and which of the two approaches could be more effective in prevention. In our study, it seems that setting a range for % suppression of EF and FS could be more efficient in identifying early cardiotoxicity by counteracting the intra-individual variation of the absolute values.

In the current in depth review analysis, we did not identify differences between rat strains in terms of suppressed EF and FS values due to anthracycline administration. This is an interesting finding as it seems that the usual strains used in rat studies are equally prone to the cardiotoxic anthracycline potential. In animal models of genetically programmed hypertension and heart failure, it is found that doxorubicin administration did not lead to lower myocardial contractility compared to non-genetically modified strains ([@b102-or-44-03-0798]). In addition, in the current systematic review, acute and chronic anthracyclines cardiotoxicity models were found equally potent in inducing cardiotoxicity based on evaluated echocardiographic indices.

Currently, when assessing chemicals toxicity, cardiac effects if monitored and detected in animal studies, mainly on the tissue level, are considered by the authorities, but cardiotoxicity, as such, is not described as a separate hazard class of chemical substances through the available regulations, both at a European level and world-wide. Therefore, chemicals other than pharmaceutical agents are recognised to be cardiotoxic after having exerted such deleterious effects on humans, based on epidemiological studies. In a previous review of our research team, the cardiac pathology and function impairment due to exposure to pesticides revealed that several cardiovascular complications have been reported in animal models including electrocardiogram abnormalities, myocardial infarction, impaired systolic and diastolic performance and histopathological findings, such as haemorrhage, vacuolization, signs of apoptosis and degeneration ([@b103-or-44-03-0798]). In addition, there is evidence that short and/or long-term exposure to anabolic androgenic steroids is linked to a variety of cardiovascular complications which could be identified by using echocardiography or biochemical markers ([@b10-or-44-03-0798],[@b104-or-44-03-0798],[@b105-or-44-03-0798]). The published data suggest clearly that there is a need to establish regulatory criteria for assessing cardiotoxicity as an inherent property of a chemical substance well in advance, and characterize the risk of exposure to such chemicals through a well-developed regulatory network based on animal models, as is the case for other human health hazard classes, such as carcinogenicity. Regulatory established criteria will enable international organizations to early identify cardiotoxic effects and classify chemicals in order to avoid long-term cardiovascular complications. Specific classification criteria should be developed based on anatomical, histopathological, echocardiographic and biochemical criteria in animals developed in a way that could exclude confounding factors in the development of the observed cardiotoxicity. The results of the present study are promising in identifying echocardiographic criteria in rats for the establishment of cardiotoxicity. Further studies and meta-analyses are needed in order to evaluate other species, commonly used in research, and explore the possibility of early recognizing the onset of cardiotoxicity, possibly through monitoring of biochemical markers based on understanding of the mode of action.
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![Normal (baseline) LVEF values in rats before anthracycline administration as reported in 57 relevant studies reviewed in the present report. LVEF, left ventricular ejection fraction.](OR-44-03-0798-g01){#f2-or-44-03-0798}

![Normal (baseline) LVFS values in rats before anthracycline administration as reported in 80 relevant studies reviewed in the present report. LVFS, left ventricular fractional shortening.](OR-44-03-0798-g02){#f3-or-44-03-0798}

![Suppressed LVEF values in rats due to anthracycline toxicity as reported in 54 relevant studies reviewed in the present report. LVEF, left ventricular ejection fraction.](OR-44-03-0798-g03){#f4-or-44-03-0798}

![Suppressed LVFS values in rats due to anthracycline toxicity as reported in 78 relevant studies reviewed in the present report. LVFS, left ventricular fractional shortening.](OR-44-03-0798-g04){#f5-or-44-03-0798}

![Chemical structures of the three anthracyclines used to induce cardiotoxicity in the studies reviewed in the present report.](OR-44-03-0798-g05){#f6-or-44-03-0798}

![Percentiles distribution of % suppression of LVEF and LVFS due to anthracycline toxicity as mentioned in the studies reviewed in the present report. LVEF, left ventricular ejection fraction; LVFS, left ventricular fractional shortening.](OR-44-03-0798-g06){#f7-or-44-03-0798}

![Scatter plot of normal (baseline) and suppressed LVEF values in rats due to anthracycline toxicity as reported the studies reviewed in the present report. LVEF, left ventricular ejection fraction.](OR-44-03-0798-g07){#f8-or-44-03-0798}

![Scatter plot of normal (baseline) and suppressed LVFS values in rats due to anthracycline toxicity as reported in the studies reviewed in the present report. LVFS, left ventricular fractional shortening.](OR-44-03-0798-g08){#f9-or-44-03-0798}

![Normal and suppressed LVEF and LVFS values for the two main rat strains used in the studies reviewed in the present report. LVEF, left ventricular ejection fraction; LVFS, left ventricular fractional shortening.](OR-44-03-0798-g09){#f10-or-44-03-0798}

###### 

Treatment protocol and main findings of the studies that examined anthracyclines cardiotoxicity in rats reviewed in the present report.

  Publication                                  No. of animals/rat strain/sex   Anthracycline administered   Anthracycline total dose     Duration                 Summary of findings                  Calculations          
  -------------------------------------------- ------------------------------- ---------------------------- ---------------------------- ------------------------ ------------------------------------ --------------------- --
  Zhang *et al* ([@b14-or-44-03-0798])         30/Sprague Dawley               Doxorubicin                  1 mg/kg                      Daily doses              Cardiac dysfunction                  Values calculated     
                                               rats/male                       (brand name Adriamycin)                                   for 2 weeks              (parameters monitored:               manually by the       
                                                                                                                                                                  diastolic left ventricular           authors of this       
                                                                                                                                                                  internal dimension, systolic         review                
                                                                                                                                                                  left ventricular internal                                  
                                                                                                                                                                  dimension, LVEF and LVFS)                                  
  Tian *et al* ([@b15-or-44-03-0798])          70/Sprague Dawley               Doxorubicin                  3.0 mg/kg                    Once a week              Cardiomyopathy                       Values provided       
                                               rats/Male                                                                                 for 6 weeks                                                   in the manuscript     
  Andreadou *et al* ([@b16-or-44-03-0798])     90/Wistar rats/male             Doxorubicin                  18 mg/kg, ip                 6 equal doses            Cardiomyopathy                       Values provided       
                                                                                                                                         for 2 weeks              (parameters monitored:               in the manuscript     
                                                                                                                                                                  cardiac geometry, function                                 
                                                                                                                                                                  and histopathology)                                        
  Oliveira *et al* ([@b17-or-44-03-0798])      20/Wistar rats/male             Doxorubicin                  5 mg/kg, ip                  Once a week              Ventricular dysfunction              Values provided       
                                                                                                                                         for 4 weeks                                                   in the manuscript     
  Hydock *et al* ([@b18-or-44-03-0798])        46/Sprague-Dawley               Doxorubicin                  10 mg/kg ip                  Acute                    Parameters altered:                  Values provided       
                                               rats/Male                                                                                 administration           LVFS and LVPWT                       in the manuscript     
                                                                                                                                         (bolus)                                                                             
  Fernandez-Fernandez                          36/Sprague-Dawley rats          Doxorubicin                  18 mg/kg                     Over 12 days             Cardiac function altered             Values provided       
  *et al* ([@b19-or-44-03-0798])               Wistar rats Fischer-344                                                                                            (LVFS, left ventricular              in the manuscript     
                                               rats/NM                                                                                                            developed pressure,                                        
                                                                                                                                                                  contractility and relaxation,                              
                                                                                                                                                                  cardiac capillary permeability)                            
  Todorova *et al* ([@b20-or-44-03-0798])      27/Fisher 344 rats/female       Doxorubicin                  12 mg/kg                     Twice per week           Parameters monitored:                Values provided       
                                                                                                            (1.5 mg/kg each)             for 4 weeks              Plasma levels of troponin I          in the manuscript     
                                                                                                                                                                  Left ventricle (LV) function,                              
                                                                                                                                                                  LV PWT, LV volume,                                         
                                                                                                                                                                  LVEF, LVFS                                                 
  Vasić *et al* ([@b21-or-44-03-0798])         68/Wistar rats/male             Doxorubicin                  15 mg/kg ip                  Every other day          Parameters monitored:                Values provided       
                                                                                                                                         for 2 weeks              Echocardiography,                    in the manuscript     
                                                                                                                                                                  serum cardiac troponins,                                   
                                                                                                                                                                  heart rate variability and                                 
                                                                                                                                                                  blood pressure variability                                 
  Mathias *et al* 22)                          64/Wistar rats/male             Doxorubicin                  20 mg/kg ip                  Acute administration     Altered LVFS                         Values provided       
                                                                                                                                         (a single injection)                                          in the manuscript     
  Wang *et al* ([@b23-or-44-03-0798])          40/Sprague-Dawley               Doxorubicin                  15 mg/kg ip                  Acute administration     Altered LVEF, LVFS                   Values calculated     
                                               rats/male                       (brand name Adriamycin)                                   (a single injection)     and LV outflow                       manually by the       
                                                                                                                                                                                                       authors of this       
                                                                                                                                                                                                       review                
  Arozal *et al* ([@b24-or-44-03-0798])        25/Sprague-Dawley               Daunorubicin                 3 mg/kg/day                  Every other day          Altered cardiac function             Values provided       
                                               rats/male                                                    (18 mg/kg total dose)        for 12 days              (haemodynamic status                 in the manuscript     
                                                                                                                                                                  and echocardiography)                                      
  Argun *et al* ([@b25-or-44-03-0798])         40/10-week-old                  Doxorubicin                  4 mg/kg/dose to              Twice a week             Parameters monitored:                Values provided       
                                               Wistar albino rats/male                                      a cumulative dose            for 2 weeks              Serum BNP and C-type                 in the manuscript     
                                                                                                            of 16 mg/kg, ip                                       natriuretic peptide                                        
                                                                                                                                                                  LV functions by                                            
                                                                                                                                                                  echocardiography                                           
                                                                                                                                                                  and histological                                           
                                                                                                                                                                  assessment                                                 
  Tatlidede *et al* ([@b26-or-44-03-0798])     32/Wistar albino rats of        Doxorubicin                  20 mg/kg, ip                 Every other day          Parameters monitored:                Values provided       
                                               both sexes                                                                                for 2 weeks              BP and HR,                           in the manuscript     
                                                                                                                                                                  echocardiography                                           
                                                                                                                                                                  Lactate dehydrogenase                                      
  Razmaraii *et al* ([@b27-or-44-03-0798])     24/adult Wistar rats/male       Doxorubicin                  2 mg/kg/48 h                 Over a 12-day period     Parameters monitored:                Values provided       
                                                                                                                                                                  LVSP, LVDP, rate of                  in the manuscript     
                                                                                                                                                                  rise/drop of LV pressure,                                  
                                                                                                                                                                  LVEF, LVFS, contractility                                  
  Gziri *et al* ([@b28-or-44-03-0798])         43/ pregnant Wistar             Doxorubicin                  10 or 20 mg/kg i.v.          On 18th day of           Altered left ventricular             Values provided       
                                               rats/female                                                                               pregnancy                function                             in the manuscript     
  Oliveira *et al* ([@b29-or-44-03-0798])      29/adult Wistar rats/male       Doxorubicin                  Accumulated doses of         Four weekly              Myocardial fibrosis                  Values provided       
                                                                                                            8 (n=8), 12 (n=7), and       injections               Altered left ventricular             in the manuscript     
                                                                                                            16 (n=7) mg/kg, ip           over 8 weeks             systolic function                                          
  Carvalho *et al* ([@b30-or-44-03-0798])      64/Wistar rats/male             Doxorubicin                  20 mg/kg, ip                 Acute                    LVEF monitored                       Values provided       
                                                                                                                                         administration                                                in the manuscript     
                                                                                                                                         (a single injection)                                                                
  Stewart *et al* ([@b31-or-44-03-0798])       72/Sprague Dawley               Doxorubicin                  15 mg/kg, ip                 Acute administration     Parameters monitored:                Values provided       
                                               rats/male                                                                                 (a bolus injection)      LV septal and PWT,                   in the manuscript     
                                                                                                                                                                  LVESd, LVEDd, mitral                                       
                                                                                                                                                                  and aortic valve blood                                     
                                                                                                                                                                  flow profiles, heart dimensions                            
  Polegato *et al* ([@b32-or-44-03-0798])      35/Wistar rats/male             Doxorubicin                  20 mg/kg, ip                 Acute administration     Parameters monitored:                Values provided       
                                                                                                                                         (a single dose)          LVFS, isovolumetric                  in the manuscript     
                                                                                                                                                                  relaxation time and                                        
                                                                                                                                                                  myocardial passive stiffness                               
  Lee *et al* ([@b33-or-44-03-0798])           20/Sprague Dawley rats/male     Doxorubicin                  Cumulative dose:             Once every two days      Impaired LV function                 Values calculated     
                                                                                                            20 mg/kg, ip                 for 6 times              and performance                      manually by the       
                                                                                                                                                                                                       authors of this       
                                                                                                                                                                                                       review                
  Cheah *et al* ([@b34-or-44-03-0798])         29/Wistar rats/male             Doxorubicin                  5 mg/kg, iv                  Acute administration     Parameters monitored:                Values provided       
                                                                                                                                         (a single dose)          BP, HR, LVED volume,                 in the manuscript     
                                                                                                                                                                  other echocardiographic                                    
                                                                                                                                                                  parameteres                                                
  Li *et al* ([@b35-or-44-03-0798])            48/adult Sprague-Dawley         Doxorubicin                  Cumulative dose:             Over a 4-week period     Parameters monitored:                Values provided       
                                               rats/male                                                    16 mg/kg, ip                                          serum BNP level                      in the manuscript     
                                                                                                                                                                  LVEDd, LVESd, LVEF, LVFS                                   
  Dundar *et al* ([@b36-or-44-03-0798])        28/adult Wistar albino          Doxorubicin                  15 mg/kg, ip                 Acute administration     Parameters monitored:                Values provided       
                                               rats/female                                                                               (a single dose)          LVIDd and LVISd                      in the manuscript     
                                                                                                                                                                  via the parasternal long                                   
                                                                                                                                                                  axis two-dimensional images.                               
                                                                                                                                                                  LVFS and LVEF                                              
  Barış *et al* ([@b37-or-44-03-0798])         31/Sprague-Dawley               Doxorubicin                  25 mg/kg, ip                 For 12--14 days          Parameters monitored:                Values provided       
                                               rats/male                                                                                                          left ventricular ejection f          in the manuscript     
                                                                                                                                                                  raction (LVEF), LVFS and                                   
                                                                                                                                                                  mitral lateral annulus (s')                                
                                                                                                                                                                  velocity + left ventricular                                
                                                                                                                                                                  end-diastolic and end-systolic                             
                                                                                                                                                                  diameters                                                  
  Lu *et al* ([@b38-or-44-03-0798])            60/Sprague-Dawley               Doxorubicin                  2.5mg/kg/week, ip            For 6 weeks              Parameters monitored:                Values provided       
                                               rats/male                                                                                                          LVFS and LVEF                        in the manuscript     
  O\'Connell *et al* ([@b39-or-44-03-0798])    115/adult Wistar rats/male      Doxorubicin                  2.5 mg/kg, ip                6 doses over a period    Parameters monitored:                Values provided       
                                                                                                            (cumulative dose             of 2 weeks               left ventricular systolic            in the manuscript     
                                                                                                            15 mg/kg)                                             and diastolic dimensions and                               
                                                                                                            2 mg/kg, ip (cumulative      Once a week              EF                                                         
                                                                                                            dose 18 mg/kg)               for 9 weeks                                                                         
  Chang *et al* ([@b40-or-44-03-0798])         71/Sprague-Dawley rats/nm       Doxorubicin                  3 mg/kg/day, iv              Once a week              Parameters monitored:                Values provided       
                                                                                                                                         for 6 weeks              SWT and PWT, LVED                    in the manuscript     
                                                                                                                                                                  dimensions, LVES dimensions,                               
                                                                                                                                                                  LVEF                                                       
  Teng *et al* ([@b41-or-44-03-0798])          46/Sprague-Dawley               Doxorubicin                  2 mg/kg, ip                  Once a week for 8        Parameters monitored:                Values provided       
                                               rats/male                                                                                 weeks                    LVED dimensions, LVES                in the manuscript     
                                                                                                                                                                  dimensions, FS                                             
  Kim *et al* ([@b42-or-44-03-0798])           61/Sprague-Dawley               Doxorubicin                  1.25 mg/kg, ip               Every other day for      LV systolic/diastolic                Values provided       
                                               rats/male                                                                                 1 month (16 times)       dysfunction                          in the manuscript     
  Kondru *et al* ([@b43-or-44-03-0798])        24/Wistar rats/male             Doxorubicin                  2 mg/kg, ip                  Once in a week           Myocardial dysfunction               Values calculated     
                                                                                                                                         for 5 weeks                                                   manually by the       
                                                                                                                                                                                                       authors of this       
                                                                                                                                                                                                       review                
  Moriyama *et al* ([@b44-or-44-03-0798])      66/Crl:CD(SD) rats/male         Doxorubicin                  2 mg/kg, iv                  Once weekly,             Parameters monitored:                Values provided       
                                                                                                                                         for 6 weeks              LVEDd, LVESd, LVFS                   in the manuscript     
  Burdick *et al* ([@b45-or-44-03-0798])       20/Crl:CD(SD) rats/male         Doxorubicin                  2 mg/kg, ip                  Once a week              Parameters monitored:                Values calculated     
                                                                                                                                         for 6 weeks              LVFS                                 manually by the       
                                                                                                                                                                                                       authors of this       
                                                                                                                                                                                                       review                
  Ammar *et al* ([@b46-or-44-03-0798])         50/Wistar rats/male             Doxorubicin                  2.5 mg/kg, ip                3 times a week           Parameters monitored:                Values calculated     
                                                                                                                                         for 2 weeks              LVED dimensions                      manually by the       
                                                                                                                                                                  and LVSD dimensions, FS              authors of this       
                                                                                                                                                                                                       review                
  Calvé *et al* ([@b47-or-44-03-0798])         21/Sprague-Dawley               Doxorubicin                  3 mg/kg                      Acute administration     Parameters monitored:                Values provided       
                                               rats/female                                                                               (on postnatal            IVSd, LVPWd, LVIDd,                  in the manuscript     
                                                                                                                                         day 26th)                LVISd                                                      
  Shen *et al* ([@b48-or-44-03-0798])          150/Sprague-Dawley              Doxorubicin                  1 mg/kg, ip                  Twice a week             Parameters monitored:                Values provided       
                                               rat/male                                                     2 mg/kg, ip (cumulative      Once a week              LVESd, LVEDd, LVEF                   in the manuscript     
                                                                                                            dose 12 mg/kg)               for 6 weeks                                                                         
  Wu *et al* ([@b49-or-44-03-0798])            32/Sprague-Dawley rat/male      Doxorubicin                  2.5 mg/kg, ip                Every second day         Parameters monitored:                Values calculated     
                                                                                                            (cumulative dose             for 6 times              LVEDP, LVESP and left                manually by the       
                                                                                                            15 mg/kg)                                             ventricular pressure                 authors of this       
                                                                                                                                                                  (±dP/dtmax), LVEF and LVFS           review                
  Shoukry *et al* ([@b50-or-44-03-0798])       32/Wister rats/male             Doxorubicin                  2.5 mg/kg, ip                2 weeks                  Parameters monitored:                Values calculated     
                                                                                                                                                                  LVIDd, LVIDs, LVFS and               manually by the       
                                                                                                                                                                  LVEF                                 authors of this       
                                                                                                                                                                                                       review                
  Niu *et al* ([@b51-or-44-03-0798])           26/Sprague Dawley               Doxorubicin                  Each dose consisted of       For 2 weeks on days      Parameters monitored:                Values provided       
                                               rats/male                                                    1, 1, 2, 2, 3, 3, 4          1st, 3rd, 5th, 7th,      IVSd, IVSs, LVPWd and                in the manuscript     
                                                                                                            and 4 mg/kg, ip              9th, 11th, 13th and      LVPWs, LVIDd, LVIDs                                        
                                                                                                            (cumulative dose             15th, respectively       were measured on left                                      
                                                                                                            20 mg/kg)                                             ventricular long-axis areas.                               
                                                                                                                                                                  LVEF and LVFS                                              
  Boutagy *et al* ([@b52-or-44-03-0798])       20/Wistar rats                  Doxorubicin                  2.15 mg/kg, ip               Every 3 days             Impaired systolic function and       Values calculated     
                                                 (Crl:Wl)/male                                              (cumulative dose             for 21 days              LV volumes and dimensions.           manually by the       
                                                                                                            15 mg/kg)                                             Parameters monitored:                authors of this       
                                                                                                                                                                  echocardiographic variables          review                
                                                                                                                                                                  (LVEF, global longitudinal strain,                         
                                                                                                                                                                  global radial strain, LVEDV,                               
                                                                                                                                                                  LVESV, relative PWT                                        
  Lee *et al* ([@b53-or-44-03-0798])           150/Fischer rats/male           Doxorubicin                  2.5 mg/kg, ip                Every other day          Altered LV function                  Values calculated     
                                                                                                            (cumulative dose             for 2 weeks              Parameters monitored:                manually by the       
                                                                                                            15 mg/kg)                                             LVFS, LVEDd and LVESd,               authors of this       
                                                                                                                                                                  LV end diastolic volume              review                
                                                                                                                                                                  (LVEDV), right basal                                       
                                                                                                                                                                  ventricular diastolic diameter                             
                                                                                                                                                                  (RVD1), and the RV fractional                              
                                                                                                                                                                  area change (RVFAC)                                        
  da Silva *et al* ([@b54-or-44-03-0798])      52/Wistar rats/female           Doxorubicin                  1.25 mg/kg, ip               Three times a week       Parameters monitored:                Values calculated     
                                                                                                                                         for 2 weeks              aorta-to-left atrial diameter        manually by the       
                                                                                                                                                                  ratio, LVESd, LVEF                   authors of this       
                                                                                                                                                                                                       review                
  Mao *et al* ([@b55-or-44-03-0798])           160/Sprague-Dawley              Doxorubicin                  2 mg/kg, ip                  Once a week for          Parameters monitored:                Values provided       
                                               rats/male                                                                                 8 consecutive weeks      LVEDd, LVESd, LVPWT,                 in the manuscript     
                                                                                                                                                                  interventricular septum                                    
                                                                                                                                                                  thickness (IVST), LVEF, LVFS                               
  Deng *et al* ([@b56-or-44-03-0798])          42/Sprague-Dawley               Doxorubicin                  2.5 mg/kg, ip                6 injections             Parameters monitored:                Values calculated     
                                               rats/male                       (brand name Adriamycin)      (cumulative 15 mg/kg)        over 2 weeks             LV dimensions, LVFS, LVEF            manually by the       
                                                                                                                                                                                                       authors of this       
                                                                                                                                                                                                       review                
  Bertinchant *et al* ([@b57-or-44-03-0798])   45/Wistar rats/male             Doxorubicin                  1.5 mg/kg, iv,               Once a week for          Parameters monitored:                Values provided       
                                                                                                            (cumulative dose             up to 8 weeks            LVEDd, LVESd and LVFS                in the manuscript     
                                                                                                            12 mg/kg)                                                                                                        
  Sun *et al* ([@b58-or-44-03-0798])           70/Sprague-Dawley               Doxorubicin                  2.5 mg/kg, ip                Once a week for          Parameters monitored:                Values provided       
                                               rats/male                                                                                 6 consecutive weeks      LVEF, LVEDd, LVESd                   in the manuscript     
                                                                                                                                                                  and LVFS                                                   
  Guerra *et al* ([@b59-or-44-03-0798])        12/SHR rats/male                Doxorubicin                  1.5 mg/kg, ip                Once a week              Parameters monitored:                Values provided       
                                                                                                            (cumulative dose             for 9 weeks              LVEDd, LVESd and LVEF                in the manuscript     
                                                                                                            13.5 mg/kg)                                                                                                      
  Gao *et al* ([@b60-or-44-03-0798])           90/Wistar albino rats/male      Doxorubicin                  2 mg/kg, ip                  Every 3 days             Parameters monitored:                Values calculated     
                                                                                                                                         for 30 days              The interventricular septal          manually by the       
                                                                                                                                                                  thickness at diastole, left          authors of this       
                                                                                                                                                                  ventricular internal diameter        review                
                                                                                                                                                                  in diastole and systole,                                   
                                                                                                                                                                  LVPWd at diastole, EF, FS                                  
  Chen *et al* ([@b61-or-44-03-0798])          60/Sprague-Dawley               Doxorubicin                  2.5 mg/kg, ip                6 injections             Parameters monitored:                Values calculated     
                                               rats/male                                                                                 over 2 weeks             LVAW, LVPWT, LVIDd                   manually by the       
                                                                                                                                                                  were measured in systole             authors of this       
                                                                                                                                                                  and diastole.                        review                
                                                                                                                                                                  EF, FS and LV volume at                                    
                                                                                                                                                                  end-systole and end-diastole                               
  Li *et al* ([@b62-or-44-03-0798])            56/Sprague-Dawley               Epirubicin                   8 mg/kg, ip                  Every five days for      Parameters monitored:                Values calculated     
                                               rats/male                                                                                 a total of three         LV dimensions and wall               manually by the       
                                                                                                                                         injections               thickness, EF, FS                    authors of this       
                                                                                                                                                                                                       review                
  Schwarz *et al* ([@b8-or-44-03-0798])        60/Sprague-Dawley               Doxorubicin                  2.5 mg/kg, iv                Once a week              Left ventricular end-systolic        Values provided       
                                               rats/female                     (brand name Adriamycin)                                   for 10 weeks             and end-diastolic diameters, FS      in the manuscript     
  Leontyev *et al* ([@b63-or-44-03-0798])      46/Sprague-Dawley               Doxorubicin                  2.5 mg/kg, ip                Once a week              LV end-systolic diameter             Values provided       
                                               rats/male                                                                                 for 9 weeks              (LVESD) and LV end-diastolic         in the manuscript     
                                                                                                                                                                  diameter (LVEDD) + FS                                      
  Merlet *et al* ([@b64-or-44-03-0798])        158/Sprague-Dawley              Doxorubicin                  2.5mg/kg, ip                 6 injections             LV end-diastolic and -systolic       Values calculated     
                                               rats/male                                                    (total 15 mg/kg)             over 2 weeks             diameters (LVEDD and                 manually by the       
                                                                                                                                                                  LVESD), diastolic posterior          authors of this       
                                                                                                                                                                  wall thicknesses (dPWth).            review                
                                                                                                                                                                  \+ LV end diastolicand systolic                            
                                                                                                                                                                  volumes (LVEDV and VESV)                                   
                                                                                                                                                                  to assess LV ejection fraction                             
                                                                                                                                                                  (LVEF), whereas LV shortening                              
                                                                                                                                                                  fraction (LVSF)                                            
  Ozkanlar *et al* ([@b65-or-44-03-0798])      40/Sprague-Dawley               Doxorubicin                  2.5 mg/kg, iv                Once a week              Left ventricular ejection            Values provided       
                                               rats/male                                                                                 for 3 weeks              fraction (LVEF) and left             in the manuscript     
                                                                                                                                                                  ventricular fractional shortening                          
                                                                                                                                                                  (LVFS)                                                     
  Hong *et al* ([@b66-or-44-03-0798])          12/Sprague-Dawley               Doxorubicin                  5 mg/ week                   Once a week              FS and ejection fraction +           Values provided       
                                               rats/male                       (brand name Adriamycin)                                   for 3 weeks              interventricular septal              in the manuscript     
                                                                                                                                                                  dimension diastole; LV                                     
                                                                                                                                                                  internal dimension diastole;                               
                                                                                                                                                                  LV posterior wall dimension                                
                                                                                                                                                                  diastole; interventricular                                 
                                                                                                                                                                  septal dimension systole;                                  
                                                                                                                                                                  LV internal dimension                                      
                                                                                                                                                                  systole; LV posterior                                      
                                                                                                                                                                  wall dimension systole                                     
  Teraoka *et al* ([@b67-or-44-03-0798])       75/Wistar rats/male             Doxorubicin                  1 mg/kg, ip                  15 times over a          LV diameter of the systole           Values provided       
                                                                               (brand name Adriamycin)      (cumulative dose             period of 3 weeks        LVDs + LV diameter of                in the manuscript     
                                                                                                            15 mg/kg)                                             the diastole LVDd.                                         
                                                                                                                                                                  \+ %fractional shortening                                  
  Hamed *et al* ([@b68-or-44-03-0798])         130/Wistar rats                 Doxorubicin                  Cumulative dose of           3 weeks                  LV diameter                          Values provided       
                                               (Harlan)/male                                                15 mg/kg                                              in systole (LVIDs)                   in the manuscript     
                                                                                                                                                                  LVIDd, LV diameter in diastole;                            
                                                                                                                                                                  IVSd, intra ventricular septum                             
                                                                                                                                                                  in diastole                                                
                                                                                                                                                                  LV posterior wall thickness                                
                                                                                                                                                                  in diastole (LVPWd)                                        
  Gabrielson *et al* ([@b69-or-44-03-0798])    21/Sprague-Dawley               Doxorubicin                  Cumulative dose of 15        Six or three weekly      Interventricular septum              Values calculated     
                                               rats/female                                                  or 7.5 mg/kg                 doses, respectively      diastole (IVSd) and                  manually by the       
                                                                                                                                                                  left ventricular posterior           authors of this       
                                                                                                                                                                  wall thickness at end diastole       review                
                                                                                                                                                                  (PWTED)                                                    
                                                                                                                                                                  \+ LV chamber diameters were                               
                                                                                                                                                                  measured at the end of diastole                            
                                                                                                                                                                  (LVEDd) and systole                                        
                                                                                                                                                                  (LVESd). EF%                                               
  Yu *et al* ([@b70-or-44-03-0798])            63/Sprague-Dawley               Doxorubicin                  2.5 mg/kg, ip                Once a week              LV shortening (LVFS) was             Values provided       
                                               rats/male                                                                                 for 6 weeks              calculated as (LVED~d~-              in the manuscript     
                                                                                                                                                                  LVESd)/LVEDd 9 100,                                        
                                                                                                                                                                  where LVEDd is LV                                          
                                                                                                                                                                  end-diastolic diameter and                                 
                                                                                                                                                                  LVESD is LV end-systolic                                   
                                                                                                                                                                  diameter                                                   
                                                                                                                                                                  \+ LV ejection fraction                                    
  Bai *et al* ([@b71-or-44-03-0798])           Rats                            Doxorubicin                  6 injections total           Within 2 weeks           LVEF; LVFS; LVED~d~                  Values provided       
                                                                                                            15 mg/kg)                                             and LVESd                            in the manuscript     
  Lu *et al* ([@b72-or-44-03-0798])            48/Sprague-Dawley               Doxorubicin                  1 mg/kg on the 2nd and                                LV internal end-diastolic            Values calculated     
                                               rats/male                                                    4th days, 2 mg/kg on the                              diameter (diastolic LVID)            manually by the       
                                                                                                            6th and 8th days,                                     and the posterior wall               authors of this       
                                                                                                            3 mg/kg on the 10th                                   end-diastolic thickness              review                
                                                                                                            and 12th days, and                                    (diastolic LVPW) + LV                                      
                                                                                                            4 mg/kg on the 14th                                   diastolic volume (diastolic                                
                                                                                                            and 16th days, ip                                     LVV) and function indexes                                  
                                                                                                                                                                  (stroke volume, EF and FS)                                 
  Wachtman *et al* ([@b73-or-44-03-0798])      30/Sprague-Dawley               Doxorubicin                  2.5 mg/kg, iv                Once a week for          FS                                   Values provided       
                                               rats/female                                                                               a total of 6 doses                                            in the manuscript     
  Zhang *et al* ([@b74-or-44-03-0798])         40/Wistar outbred rats/male     Doxorubicin                  2.5 mg/kg, ip                Three times per week     The LV end-systolic diameter         Values provided       
                                                                               (brand name Adriamycin)      (total 15 mg/kg)             for one week. After a    (LVSD), the LV end-diastolic         in the manuscript     
                                                                                                                                         two-week interval,       diameter (LVDD), the LV                                    
                                                                                                                                         administration for       end-systolic volume (LVSV)                                 
                                                                                                                                         another week. These      and the LV end-diastolic                                   
                                                                                                                                         steps were conducted     volume (LVDV) + The LV                                     
                                                                                                                                         6 times                  ejection fraction (LVEF)                                   
                                                                                                                                                                  and the LV shortening                                      
                                                                                                                                                                  fraction (LVFS)                                            
  Chen *et al* ([@b75-or-44-03-0798])          39/ Wister rats/male            Doxorubicin                  2.5 mg/kg, ip                Six times for 2 weeks    LV end diastolic diameter            Values provided       
                                                                                                                                                                  (LVEDd), LV end systolic             in the manuscript     
                                                                                                                                                                  diameter (LVESd) and ejection                              
                                                                                                                                                                  fraction (EF) + FS + LV                                    
                                                                                                                                                                  systolic pressure (LVSP), LV                               
                                                                                                                                                                  end diastolic pressure (LVEDP),                            
                                                                                                                                                                  LV maximum dP/dt and                                       
                                                                                                                                                                  LV minimum dP/dt                                           
  Ha *et al* ([@b76-or-44-03-0798])            60/Wistar rats/male             Doxorubicin                  2 mg/kg, iv                  Once a week for 2, 4,    LV performance                       Values calculated     
                                                                               (brand name Adriamycin)                                   6 or 8 weeks,            LV dimensions (end-diastolic         manually by the       
                                                                                                                                         consecutively            and end-systolic diameter)           authors of this       
                                                                                                                                                                  \+ EF                                review                
  Emanuelo *et al* ([@b77-or-44-03-0798])      40/Sprague-Dawley               Doxorubicin                  2.5 mg/kg, ip                Every second day         LV systolic pressure (LVSP)          Values calculated     
                                               rats/male                                                    (total 15 mg/kg)             for a period of          Diastolic and systolic               manually by the       
                                                                                                                                         2 weeks                  LV wall thickness, LVEDD,            authors of this       
                                                                                                                                                                  and LVESD were measured              review                
                                                                                                                                                                    + percent LV FS                                          
  Lim (78)                                     52/Sprague-Dawley               Doxorubicin                  2.5 mg/kg, ip                Six times                LVES dimensions, LVED                Values provided       
                                               rats/male                                                                                 over 2 weeks             dimensions, LVFS                     in the manuscript     
  Hydock *et al* ([@b79-or-44-03-0798])        147/Sprague-Dawley              Doxorubicin                  10 mg/kg, ip                 Acute administration     SWT during systole (SWs)             Values calculated     
                                               rats/male                                                                                 (bolus injection)        and diastole (SWd), PWT and          manually by the       
                                                                                                                                                                  PWT during diastole (PWd),           authors of this       
                                                                                                                                                                  LVEDd, LVESd, FS                     review                
  Xiang *et al* ([@b80-or-44-03-0798])         37/Sprague-Dawley               Doxorubicin                  2.5 mg/kg, ip                Once a week              LVEDd and LVESd +                    Values provided       
                                               rats/male                                                                                 for 6 weeks              LV FS (%)                            in the manuscript     
  Kenk *et al* ([@b81-or-44-03-0798])          94/Sprague-Dawley               Doxorubicin                  2.5 mg/kg, ip                6 injections             LV internal diameter                 Values provided       
                                               rats/male                       (brand name Adriamycin)      (total 15 mg/kg)             over 2 weeks             (LV diastolic and systolic           in the manuscript     
                                                                                                                                                                  dimensions; LVDD and                                       
                                                                                                                                                                  LVSD), LV posterior                                        
                                                                                                                                                                  wall (LVPW), and intra-                                    
                                                                                                                                                                  ventricular septum (IVS)                                   
                                                                                                                                                                  thickness at end-diastole                                  
                                                                                                                                                                  and peak systole.                                          
                                                                                                                                                                  →LV volume in diastole                                     
                                                                                                                                                                  and systole (LVDV, LVSV),                                  
                                                                                                                                                                  stroke volume (SV),                                        
                                                                                                                                                                  EF, FS, and LV mass                                        
  Katona *et al* ([@b82-or-44-03-0798])        23/Adult Wistar rats/male       Doxorubicin                  2.5 mg/kg, ip                Three times a week       Parameters monitored:                Values provided       
                                                                               (brand name Adriamycin)                                   for 2 weeks              LVDDd and LVSDd,                     in the manuscript     
                                                                                                                                                                  FS, LAD, AOD                                               
  Hydock *et al* ([@b83-or-44-03-0798])        49/Sprague-Dawley               Doxorubicin                  1.5 mg/kg i.p of             Once a day for           Septal wall thickness at systole     Values provided       
                                               rats/female                                                  (cumulative 15 mg/kg)        10 consecutive days      (SWs) and diastole (SWd),            in the manuscript     
                                                                                                                                                                  posterior wall thickness at                                
                                                                                                                                                                  systole (PWs) and diastole                                 
                                                                                                                                                                  (PWd), LVDs and LVDd,                                      
                                                                                                                                                                  and FS                                                     
  Hou *et al* ([@b84-or-44-03-0798])           40/Wistar rats/male             Doxorubicin                  2.5 mg/kg, ip                6 times for 2 weeks      LV dimensions                        Values provided       
                                                                               (brand name Adriamycin)                                                            \[end-diastolic diameter             in the manuscript     
                                                                                                                                                                  (LVDd) and end systolic                                    
                                                                                                                                                                  diameter (LVDs)\] + % FS                                   
                                                                                                                                                                  of the LV                                                  
  Hydock *et al* ([@b85-or-44-03-0798])        74/Sprague-Dawley               Doxorubicin                  1 mg/kg, ip                  Once a day for           Septal wall thickness                Values provided       
                                               rats/male                                                    (total 10 mg/kg)             10 consecutive days      at systole (SWs) and diastole        in the manuscript     
                                                                                                                                                                  (SWd), posterior wall thickness                            
                                                                                                                                                                  at systole (PWs) and diastole                              
                                                                                                                                                                  (PWd), LVDs and LVDd.                                      
                                                                                                                                                                  \+ FS, LV mass and relative                                
                                                                                                                                                                  wall thickness (RWT).                                      
  Koh *et al* ([@b86-or-44-03-0798])           33/Wistar rats/male             Doxorubicin                  2 mg/kg, iv                  Once a week              LV dimensions (the LVDd,             Values provided       
                                                                               (brand name Adriamycin)                                   for 8 weeks              LVDs, the intraventricular           in the manuscript     
                                                                                                                                                                  septal thickness, and the LV                               
                                                                                                                                                                  posterior wall thickness) +                                
                                                                                                                                                                  \% FS of LV atrial natriuretic                             
                                                                                                                                                                  peptide; brain natriuretic peptide                         
  Carresi *et al* ([@b87-or-44-03-0798])       40/Wistar rats/male             Doxorubicin                  2.5 mg/kg, ip                6 times for 2 weeks      LVESd; LVEDd; IVSs;                  Values provided       
                                                                                                                                                                  IVSd, LVPWs and LVPWd;               in the manuscript     
                                                                                                                                                                  EF; FS                                                     
  Ma *et al* ([@b88-or-44-03-0798])            190/Wistar rats/male            Doxorubicin                  2.5 mg/kg, ip                6 times for 2 weeks      LVEDD) and LVESD                     Values provided       
                                                                                                                                                                  \+ FS + EF                             in the manuscript   
  Zhang *et al* ([@b89-or-44-03-0798])         26/Sprague-Dawley               Doxorubicin                  4 mg/kg, ip                  Twice per week           Diastolic interventricular           Values calculated     
                                               rats/male                                                    (cumulative dose             for 2 weeks              septum thickness (IVSTd),            manually by the       
                                                                                                            16 mg/kg)                                             systolic interventricular septum     authors of this       
                                                                                                                                                                  thickness (IVSTs), + EF + FS         review                
  Sun *et al* ([@b90-or-44-03-0798])           32/Sprague-Dawley               Doxorubicin                  20 mg/kg, ip                 Acute administration     (LVEF) from EDV and ESV,             Values provided       
                                               rats/male                                                    5.0 mg/kg, iv                (single dose)            \+ EDV and ESV                       in the manuscript     
                                                                                                                                                                  \+ LVFS                                                    
  Zhu *et al* ([@b91-or-44-03-0798])           50/Adult Sprague-Dawley         Doxorubicin                  2 mg/kg/week                 6 weeks                  Ejection fraction                    Values provided       
                                               rats/male                                                                                                                                               in the manuscript     
  Croteau *et al* ([@b92-or-44-03-0798])       12/ Fisher rats/male            Doxorubicin                  2 mg/kg, iv                  Once a week              Left ventricular function            Values provided       
                                                                                                                                         for 6 weeks              Left ventricle ejection fraction     in the manuscript     
  Ikegami *et al* ([@b93-or-44-03-0798])       14/Sprague-Dawley/NM            Doxorubicin                  2.5 mg/kg, ip                3 times a week           LVDd and LVFS + FS                   Values provided       
                                                                                                                                         for 2 to 6 weeks                                              in the manuscript     
  Hiona *et al* ([@b94-or-44-03-0798])         24/Sprague Dawley               Doxorubicin                  Cumulative dose of           Once a week              LVFS                                 Values provided       
                                               rats/female                                                  25 mg/kg, ip                 for 6 weeks                                                   in the manuscript     
  Tang *et al* ([@b95-or-44-03-0798])          40/Sprague-Dawley               Doxorubicin                  2.5 mg/kg, ip                Once a day for           Parameters monitored:                Values provided       
                                               rats/male                                                                                 a total of 6 times       LVEF, LVIDd, LVIDs,                  in the manuscript     
                                                                                                                                                                  LVPWd, LVPWs, left ventricle                               
                                                                                                                                                                  \% EF, and left ventricle % FS                             
  Migrino *et al* ([@b96-or-44-03-0798])       31/Sprague Dawley               Doxorubicin                  2.5 mg/kg, iv                Once a week              FS monitored                         Values provided       
                                               rats/male                                                                                 for 10 or 12 weeks                                            in the manuscript     
  Liu *et al* ([@b97-or-44-03-0798])           24/Sprague-Dawley               Doxorubicin                  Each dose consisted of       At 1st, 3rd, 5th, 7th,   Parameters monitored:                Values provided       
                                               rats/male                       (brand name Adriamycin)      1, 1, 2, 2, 3 and 3 mg/kg,   9th and 11th day,        interventricular septum              in the manuscript     
                                                                                                            ip (cumulative dose          respectively             thickness of systolic, IVSd,                               
                                                                                                            12 mg/kg)                                             LVIDd, LVISd, LVPW,                                        
                                                                                                                                                                  LVPWd, EF, FS                                              
  Liu *et al* ([@b98-or-44-03-0798])           120/Sprague Dawley              Doxorubicin                  3.3 mg/kg, iv                Once a week                                                   Values provided       
                                               rats/NM                                                                                   for 4 weeks                                                   in the manuscript     

LV, left ventricular; LVEF, LV ejection fraction; LVFS: LV fractional shortening; BNP, brain natriuretic peptide; PWT, posterior wall thickness; AWT, anterior wall thickness; SWT, septal wall thickness; BP, blood pressure; HR, heart rate; LVSP, LV systolic pressure; LVDP, LV diastolic pressure; LVEDd, LV end-diastolic diameter; LVESd, LV end-systolic diameter; LVEDV, LV end-diastolic volume; LVIDd, LV internal diastolic diameter LVISd, LV internal systolic diameter; LVPWs, LV systolic wall thickness; LVPWd, LV diastolic wall thickness; IVSd, intraventricular septum in diastole; LAD, left atrial diameter; AOD, aortic diameter; ip, intraperitoneally; iv, intravenously; NM, not mentioned; SD, Sprague-Dawley.
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